Aptuit Establishes New Company in India - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Aptuit Establishes New Company in India
Aptuit expands its drug-development capabilities with the formation of Aptuit Laurus to take advantage of the growing pharmaceutical outsourcing market in India.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

With SSCI, Aptuit gained solid-form research capabilities, and EaglePicher Pharmaceutical Services gave the company small-molecule synthesis capabilities, including those for high-potency actives. From InfoPro Solutions Aptuit obtained an informatics suite, "Clinicopia," for clinical-trials management, information technology staffing, and infrastructure that will serve as the information spine for Aptuit across all business lines. Pharma Consulting expanded the company's consulting capabilities in drug development. And the acquisition of Quintiles EDP added capabilities for Aptuit in preclinical technology, pharmaceutical sciences, and clinical packaging and logistics (CPL). Almedica further added to Aptuit's capabilities and capacity for CPL and provided a foundation for information technology infrastructure.

Aptuit builds API capabilities

A key move made by Aptuit was the acquisition of EaglePicher Pharmaceutical Services, which provided Aptuit drug-substance manufacturing capabilities to complement its existing capabilities in dosage-form manufacturing, clinical packaging, and informatics.

With the acquisition of EaglePicher Pharmaceutical Services, Aptuit has a total reactor capacity of 2,500 gallons, which includes specialized technologies in radiolabeling, high-potency API manufacturing, and cryogenics. Aptuit is investing in the former EaglePicher facilities in Harrisonville, Missouri. The investment includes upgrades to quality systems and laboratory capabilities, the addition of dryer capacity, and some additional production capabilities such as hydrogenation. The target completion date for the larger volume capacity of API manufacturing capability is August–September 2008. Aptuit also is investing in radiolabeling capability, kilo-scale laboratories, and additional process-development capabilities at its facilities in Kansas City, Missouri. The radiolabeling and kilo laboratories in Kansas City are scheduled to be on line in December 2007–January 2008.

In all, the company is spending approximately $140 million in internal capital for projects and also plans to invest an additional $100 million in Aptuit Laurus. The privately held Aptuit has raised as much as $750 million as of April 2006.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here